Dumb Money Live
Dumb Money Live
Dumb Money
$48 Billion — Our most important show ever
1 hour 7 minutes Posted Jan 24, 2023 at 6:59 pm.
0:00
1:07:26
Download MP3
Show notes

The FDA is expected to approve Tirzepatide for weight loss sometime this year and we think it could become the best selling drug of ALL TIME. Today on Dumb Money, we’ll weigh the data, size-up the opportunity, and give you the skinny on our diet drug investment thesis.

Here are the GLP-1 RA drug makers and their drugs:

Eli Lilly (ticker LLY)

Tirzepatide sold as Mounjaro for diabetes. Weight loss version expected in 2023.

Dulaglutide sold as Trulicity.

Novo Nordisk (ticker NVO)

Semaglutide sold as Ozempic and Rybelsus for diabetes and Wegovy for weight loss.

Liraglutide sold as Victoza for diabetes and Saxenda for weight loss.